Actively Recruiting

Age: 60Years +
All Genders
ID07278609

The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions

Led by McGill University Health Centre/Research Institute of the McGill University Health Centre · Updated on 2026-05-01

100

Participants Needed

1

Research Sites

13 weeks

Total Duration

On this page

Sponsors

M

McGill University Health Centre/Research Institute of the McGill University Health Centre

Lead Sponsor

T

The Arthritis Society, Canada

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating whether a tool called MedSafer, combined with educational brochures for patients, can help reduce the use of potentially inappropriate medications (PIMs) in adults aged 60 and over who have rheumatic diseases and take five or more regular medications. This study is a prospective observational quality improvement trial conducted at a rheumatology clinic to compare medication use before and after introducing these interventions. The intervention includes personalized MedSafer reports generated for physicians, which highlight deprescribing opportunities categorized by risk level, along with specific tapering instructions. Patients receive educational materials including a deprescribing fact sheet and, if applicable, bilingual EMPOWER brochures for certain medications. Participants are followed through control and intervention periods of approximately ten months each, receiving usual care first, then the intervention while continuing their routine rheumatology visits. Participants complete four study visits over 18 to 20 months, including two in-person and two virtual visits. Researchers collect data on medication changes, emergency visits, hospitalizations, and quality of life using the EQ-5D-5L questionnaire at each visit. The study measures the rate of PIM deprescribing, changes in medication count, quality of life, and serious adverse events during both periods. The involvement includes reviewing medical records and ensuring follow-up to assess the impact of the interventions on medication management.

CONDITIONS

Brief Title

The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions

Who Can Participate

Age: 60Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 60 or older
  • Followed by a rheumatologist for inflammatory arthritis, systemic autoimmune rheumatic disease, or another chronic musculoskeletal or rheumatic condition
  • Taking five or more regular medications and at least one potentially inappropriate medication (PIM)
  • Expected to have ongoing rheumatology follow-up every 3 to 9 months
Not Eligible

You will not qualify if you...

  • Unable to provide informed consent
  • Acute life-threatening illness or life expectancy less than 12 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) during routine clinical visits for eligibility screening and recruitment

Control Period

Duration - Approximately 10 months

Participants undergo usual care without access to deprescribing reports. Medication use and health outcomes are monitored.

2 in-person or virtual visits: Visit 1 (enrollment and baseline data collection) and Visit 2 (follow-up approximately 4 months later)

Intervention Period

Duration - Approximately 10 months

Participants receive physician-facing deprescribing opportunity reports and patient educational brochures to improve medication appropriateness.

2 visits: 1 in-person visit (Visit 3) to receive the intervention and 1 virtual or in-person follow-up visit (Visit 4) approximately 4 months later

Trial Site Locations

Total: 1 location

1

Montreal General Hospital, McGill University Health Centre

Montreal, Quebec, Canada, H3G1A4

Actively Recruiting

Loading map...

Research Team

A

Arielle Mendel, MD MSc

J

Jeannette Bere, BSc, LPN

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Scavenging IsoLGs in Autoimmune Disease: a Proof-of-concept ...

Systemic Lupus Erthematosus (SLE)

Actively Recruiting

1 location

Evaluation of 3D DL oZTEo in the Detection of Osseous Change...

Inflammatory Arthritis

Actively Recruiting

1 location

A Phase 1 Open Label Dose Escalation Study of HB2198, a Tetr...

Systemic Lupus Erthematosus (SLE)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here